[go: up one dir, main page]

JP2008194050A - 宿主細胞でのpaceの発現およびその使用法 - Google Patents

宿主細胞でのpaceの発現およびその使用法 Download PDF

Info

Publication number
JP2008194050A
JP2008194050A JP2008066877A JP2008066877A JP2008194050A JP 2008194050 A JP2008194050 A JP 2008194050A JP 2008066877 A JP2008066877 A JP 2008066877A JP 2008066877 A JP2008066877 A JP 2008066877A JP 2008194050 A JP2008194050 A JP 2008194050A
Authority
JP
Japan
Prior art keywords
compositions
methods
pace
expression
host cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008066877A
Other languages
English (en)
Inventor
Philip J Barr
ジェー. バール フィリップ
Anthony J Brake
ジェー. ブレイク アンソニー
Randal J Kaufman
ジェー. コーフマン ランダル
Patricia Tekamp-Olson
テカムプ−オルソン パトリシア
Louise Wasley
ワスレー ルイーズ
Polly A Wong
エイ. ウォン ポリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Genetics Institute LLC
Original Assignee
Novartis Vaccines and Diagnostics Inc
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27505162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008194050(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines and Diagnostics Inc, Genetics Institute LLC filed Critical Novartis Vaccines and Diagnostics Inc
Publication of JP2008194050A publication Critical patent/JP2008194050A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6454Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

【課題】エンドペプチダーゼを生産するための組成物および方法を提供すること。
【解決手段】エンドペプチダーゼを生産するための組成物および方法、並びに、生物学的活性のためにγ−カルボキシル化を必要とするタンパク質を含む、異種前駆体ポリペプチドの成熟ポリペプチドへのプロセシングの効率を高めるための組成物および方法を提供する。これらの組成物および方法は、二塩基性アミノ酸部位に特異的に作用する哺乳動物のエンドペプチダーゼである組換えPACEを利用するものである。
【選択図】なし

Description

Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
発明の概要
本発明は、例えば以下の項目を提供する。
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
Figure 2008194050
図1は、A.M.W. van den Ouweland et. al., Nucl. Acids Res., 18(3):664 (1990)に発表されたfurDNA配列を示す。 図1の続き。 図1の続き。 図1の続き。 図1の続き。 図1の続き。 図2は、PACEをコードする完全なcDNA配列、およびそこにコードされるアミノ酸を示し、これはヌクレオチド−320から−1までの5’非翻訳領域とヌクレオチド2383から3974までの3’非翻訳領域を含む点で上記図1と相違する。 図2の続き。 図2の続き。 図2の続き。 図2の続き。 図2の続き。 図2の続き。 図2の続き。 図2の続き。 図2の続き。 図2の続き。

Claims (1)

  1. 明細書中に記載の、組成物。
JP2008066877A 1990-11-26 2008-03-14 宿主細胞でのpaceの発現およびその使用法 Withdrawn JP2008194050A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62109290A 1990-11-26 1990-11-26
US62144390A 1990-11-29 1990-11-29
US62085990A 1990-11-29 1990-11-29
US62145790A 1990-11-30 1990-11-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP50154992A Division JP4236698B2 (ja) 1990-11-26 1991-11-26 宿主細胞でのpaceの発現およびその使用法

Publications (1)

Publication Number Publication Date
JP2008194050A true JP2008194050A (ja) 2008-08-28

Family

ID=27505162

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50154992A Expired - Lifetime JP4236698B2 (ja) 1990-11-26 1991-11-26 宿主細胞でのpaceの発現およびその使用法
JP2008066877A Withdrawn JP2008194050A (ja) 1990-11-26 2008-03-14 宿主細胞でのpaceの発現およびその使用法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP50154992A Expired - Lifetime JP4236698B2 (ja) 1990-11-26 1991-11-26 宿主細胞でのpaceの発現およびその使用法

Country Status (10)

Country Link
US (3) US5460950A (ja)
EP (2) EP0574402B2 (ja)
JP (2) JP4236698B2 (ja)
AT (1) ATE158816T1 (ja)
CA (1) CA2096418C (ja)
DE (1) DE69127829T2 (ja)
DK (1) DK0574402T3 (ja)
ES (1) ES2109336T3 (ja)
IE (1) IE914102A1 (ja)
WO (1) WO1992009698A1 (ja)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935815A (en) * 1989-10-25 1999-08-10 Katholieke Universiteit Leuven Process for micro biological production of proteins
EP0574402B2 (en) * 1990-11-26 2012-08-01 Genetics Institute, LLC Expression of pace in host cells and methods of use thereof
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
JPH07504818A (ja) * 1992-03-09 1995-06-01 カイロン コーポレイション 細胞内pace4およびpace4.1遺伝子ならびにポリペプチドに関する組成物および方法
US5846802A (en) * 1992-04-15 1998-12-08 Buxton; Frank Fungal Protease
DK1396542T3 (da) 1992-10-23 2011-06-06 Genetics Inst Llc P-selectin ligand protein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5604201A (en) * 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
CA2213734A1 (en) * 1995-02-27 1996-09-06 Abbott Laboratories A plasmid for expressing modified recombinant proteins in a bacterial system
US5942254A (en) * 1995-02-27 1999-08-24 Abbott Laboratories Phosphorylated recombinant human β-casein expressed in a bacterial system
US5710044A (en) * 1995-02-27 1998-01-20 Abbott Laboratories Plasmid for expressing phosphorylated recombinant proteins in a bacterial system
WO1996027017A1 (en) * 1995-02-27 1996-09-06 Abbott Laboratories A method for expressing modified recombinant proteins in a bacterial system
US5807702A (en) * 1995-02-27 1998-09-15 Abbott Laboratories Method for expressing phosphorylated recombinant human β-casein in a bacterial system
AT404838B (de) 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
JPH09295945A (ja) * 1996-04-30 1997-11-18 Hoechst Yakuhin Kogyo Kk 成熟型骨誘導因子の製造方法
US6518411B1 (en) * 1996-11-22 2003-02-11 University Of Iowa RGS compositions and therapeutic and diagnostic uses therefor
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
GB9704305D0 (en) * 1997-03-01 1997-04-23 Univ Manchester Procollagen assembly
US7081519B1 (en) 1997-04-24 2006-07-25 Zymogenetics, Inc. Antibodies to serine protease polypeptides
US6153420A (en) * 1997-04-24 2000-11-28 Zymogenetics, Inc. Serine protease polypeptides and materials and methods for making them
WO1998050560A1 (en) * 1997-05-06 1998-11-12 Zymogenetics, Inc. Human prohormone convertase 4
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
CA2249648A1 (en) * 1998-11-04 2000-05-04 Nabil G. Seidah Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity
ES2315022T3 (es) * 1998-11-06 2009-03-16 Novo Nordisk Health Care Ag Metodo para la produccion de fvii.
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
US6511832B1 (en) * 1999-10-06 2003-01-28 Texas A&M University System In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase
ATE406438T1 (de) * 1999-11-19 2008-09-15 Solvay Pharm Bv Menschliches homolog aus der familie der metalloproteasen
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
US20040047853A1 (en) * 2000-06-09 2004-03-11 Dahl Soren W Purified proenzyme of dipeptidyl peptidase i (pro-dppi)
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US8202973B2 (en) * 2000-10-02 2012-06-19 Novo Nordisk Health Care Ag Method for the production of vitamin K-dependent proteins
WO2002039951A2 (en) * 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
WO2002094176A2 (en) * 2001-05-18 2002-11-28 Solvay Pharmaceuticals Gmbh Use of compounds with combined nep/mp-inhibitory activity on the preparation of medicaments
EP1572885A2 (en) * 2001-08-08 2005-09-14 Genzyme Corporation Methods for treating diabetes and other blood sugar disorders
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
JP2005523723A (ja) * 2002-04-30 2005-08-11 マキシゲン ホルディングス リミテッド 第VII因子または第VIIa因子のポリペプチド変種
WO2003100053A1 (en) * 2002-05-22 2003-12-04 The Children's Hospital Of Philadelphia Compositions and methods for the treatment of hemophilia a
EP2085470B1 (en) * 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII or FVIIa variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE602004025576D1 (de) * 2003-06-19 2010-04-01 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
DK2380985T3 (en) 2003-09-23 2014-03-17 Univ North Carolina Cells expressing the vitamin K epoxide reductase, as well as their use
US20050107318A1 (en) * 2003-11-17 2005-05-19 Samuel Wadsworth Methods of treating diabetes and other blood sugar disorders
US20050196864A1 (en) * 2004-02-10 2005-09-08 Goldman Steven A. Induction and high-yield preparative purification of mesencephalic dopaminergic neuronal progenitor cells and dopaminergic neurons from human embryonic stem cells
AU2005243187A1 (en) * 2004-05-11 2005-11-24 Wyeth Oligonucleotide arrays to monitor gene expression and methods for making and using same
EP1765411B2 (en) * 2004-06-30 2017-10-11 Nektar Therapeutics Polymer-factor ix moiety conjugates
MX2007002772A (es) * 2004-09-07 2008-03-05 Archemix Corp Aptameros para el factor de von willebrand y su uso como agentes terapeuticos para la enfermedad trombotica.
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
EP1791557A4 (en) * 2004-09-07 2009-09-23 Archemix Corp MEDICAL CHEMISTRY USING APTAMERS
JP2008532544A (ja) * 2005-03-15 2008-08-21 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 活性ビタミンk依存性タンパク質を生産するための方法及び組成物
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
JP2009502140A (ja) 2005-07-22 2009-01-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 光活性化陽イオンチャネルおよびその使用
US9238150B2 (en) 2005-07-22 2016-01-19 The Board Of Trustees Of The Leland Stanford Junior University Optical tissue interface method and apparatus for stimulating cells
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US10052497B2 (en) 2005-07-22 2018-08-21 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
EP2385125A3 (en) * 2005-12-21 2012-04-11 Inspiration Biopharmaceuticals, Inc. Method of producing biologically active vitamin K dependent proteins by recombinant methods
SI2004683T1 (sl) 2006-03-24 2016-09-30 Biogen Hemophilia Inc. Pc5 kot encim za obdelavo propeptida faktorja ix
ATE444741T1 (de) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
WO2008101128A1 (en) 2007-02-14 2008-08-21 The Board Of Trustees Of The Leland Stanford Junior University System, method and applications involving identification of biological circuits such as neurological characteristics
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
CA3090908A1 (en) 2007-04-26 2008-11-06 Aptevo Biotherapeutics Llc Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
KR101660533B1 (ko) 2007-05-22 2016-10-10 박스알타 인코퍼레이티드 인간 푸린의 분취 정제 방법
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US10035027B2 (en) 2007-10-31 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Device and method for ultrasonic neuromodulation via stereotactic frame based technique
PT2574677T (pt) 2007-12-27 2017-10-19 Baxalta Inc Processos para cultura de células
SG10201805749QA (en) 2007-12-31 2018-08-30 Baxalta Inc Substantially animal protein-free recombinant furin and methods for producing same
CA2722278C (en) 2008-04-23 2020-03-31 Feng Zhang Systems, methods and compositions for optical stimulation of target cells
EP2294208B1 (en) 2008-05-29 2013-05-08 The Board of Trustees of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
ES2612052T3 (es) 2008-06-17 2017-05-11 The Board Of Trustees Of The Leland Stanford Junior University Dispositivos para la estimulación óptica de células diana, utilizando un elemento de transmisión óptica
AU2009260027B2 (en) 2008-06-17 2015-12-03 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and methods for controlling cellular development
US9101759B2 (en) 2008-07-08 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
EP2163243A1 (en) 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
NZ602416A (en) 2008-11-14 2014-08-29 Univ Leland Stanford Junior Optically-based stimulation of target cells and modifications thereto
EP2251028A1 (en) 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor
AU2011227131B2 (en) 2010-03-17 2014-11-13 The Board Of Trustees Of The Leland Stanford Junior University Light-sensitive ion-passing molecules
SG186875A1 (en) 2010-07-09 2013-02-28 Biogen Idec Hemophilia Inc Chimeric clotting factors
US9611310B2 (en) * 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
WO2012034704A1 (en) 2010-09-15 2012-03-22 Biocompatibles Uk Ltd. Treatment of vascular diseases using encapsulated cells encoding and secreting glp-1, or a fragment or variant thereof
CA2816968C (en) 2010-11-05 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Optically-controlled cns dysfunction
EP2635295B1 (en) 2010-11-05 2017-12-20 The Board of Trustees of the Leland Stanford Junior University Control and characterization of memory function
AU2011323235B2 (en) 2010-11-05 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of reward-related behaviors
EP3486253A1 (en) 2010-11-05 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
CN103313752B (zh) 2010-11-05 2016-10-19 斯坦福大学托管董事会 用于光遗传学方法的光的上转换
CN103491770B (zh) 2010-11-05 2016-06-08 斯坦福大学托管董事会 稳定阶跃函数视蛋白及其使用方法
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
US20140051832A1 (en) * 2011-03-11 2014-02-20 Universidade De São Paulo - Usp Method for the production of recombinant human factor viii
BR112013030880B1 (pt) 2011-06-02 2022-04-12 Takeda Pharmaceutical Company Limited Composição aquosa estabilizada de furina recombinante
CA2859364C (en) 2011-12-16 2019-05-07 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
HK1205188A1 (en) * 2012-02-14 2015-12-11 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
US20140024701A1 (en) 2012-02-21 2014-01-23 Circuit Therapeutics, Inc. Compositions and Methods for Treating Neurogenic Disorders of the Pelvic Floor
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
CA2906756A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of behavioral state
US9636380B2 (en) 2013-03-15 2017-05-02 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of inputs to the ventral tegmental area
US10588949B2 (en) 2013-03-15 2020-03-17 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
CA2908864A1 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Devices, systems and methods for optogenetic modulation of action potentials in target cells
EP3033427A4 (en) 2013-08-14 2017-05-31 The Board Of Trustees Of The University Of the Leland Stanford Junior University Compositions and methods for controlling pain
AU2015268149B2 (en) 2014-05-26 2021-03-11 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
TWI666319B (zh) 2014-08-12 2019-07-21 美商巴克斯歐塔公司 在分泌furin之哺乳動物表現系統中生產經完全加工且具功能性之因子X
EP3194446B1 (en) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
WO2016172479A1 (en) 2015-04-22 2016-10-27 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
US10568516B2 (en) 2015-06-22 2020-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for imaging and/or optogenetic control of light-responsive neurons
US11294165B2 (en) 2017-03-30 2022-04-05 The Board Of Trustees Of The Leland Stanford Junior University Modular, electro-optical device for increasing the imaging field of view using time-sequential capture

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2855719A1 (de) 1978-12-22 1980-07-10 Siemens Ag Zahnaerztliche handstueckanordnung
US4336336A (en) 1979-01-12 1982-06-22 President And Fellows Of Harvard College Fused gene and method of making and using same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU545912B2 (en) 1980-03-10 1985-08-08 Cetus Corporation Cloned heterologous jive products in bacillies
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
ES511741A0 (es) 1981-04-29 1983-06-01 Biogen Nv Un metodo para producir un polipeptido.
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
US4546083A (en) 1983-04-22 1985-10-08 Stolle Research & Development Corporation Method and device for cell culture growth
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
JPS59205983A (ja) 1983-04-28 1984-11-21 ジエネツクス・コ−ポレイシヨン 異種遺伝子を原核微生物で発現させる方法
US4663280A (en) 1983-05-19 1987-05-05 Public Health Research Institute Of The City Of New York Expression and secretion vectors and method of constructing vectors
US4745051A (en) * 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
EP0136907A3 (en) 1983-10-03 1986-12-30 Genentech, Inc. A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
ATE102250T1 (de) 1984-05-11 1994-03-15 Chiron Corp Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.
US5077204A (en) * 1984-06-21 1991-12-31 Chiron Corporation Yeast endopeptidase for basic amino-acid site cleavage, preparation and use
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
DE3679343D1 (de) 1985-03-28 1991-06-27 Chiron Corp Expression durch verwendung von fusionsgenen fuer proteinproduktion.
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4770999A (en) * 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
US4865974A (en) 1985-09-20 1989-09-12 Cetus Corporation Bacterial methionine N-terminal peptidase
DE3750378T2 (de) 1986-05-02 1995-01-19 Gist Brocades Nv Sekretionssignal-Selektionsvektoren für extrazelluläre Proteinsynthese in Bazillen.
EP0246709A1 (en) * 1986-05-20 1987-11-25 Stichting Katholieke Universiteit Recombinant DNA and cDNA, mRNA, protein, antibodies, and a method of detecting tumor cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
WO1988002406A2 (en) 1986-10-02 1988-04-07 Massachusetts Institute Of Technology Methods of regulating metabolic stability of proteins
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ハイブリツドプロモ−タ−、発現調節dna配列および発現ベクタ−
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US4870023A (en) * 1987-03-16 1989-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
ATE103333T1 (de) 1987-03-23 1994-04-15 Zymogenetics Inc Hohe proteinsyntheserate in hefe.
GB8712540D0 (en) * 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US4929553A (en) * 1987-05-29 1990-05-29 Canadian Patents & Development Ltd. Protease for specific processing of secreted proteins
US5041378A (en) * 1987-08-11 1991-08-20 Cetus Corporation Procaryotic xylose isomerase muteins
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4973551A (en) 1988-01-15 1990-11-27 Merck & Co., Inc. Vector for the expression of fusion proteins and protein immunogens
JP2643968B2 (ja) * 1988-02-03 1997-08-25 サントリー株式会社 Kex2エンドプロテアーゼ及びその製造方法
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
JP2693800B2 (ja) 1988-12-28 1997-12-24 甲府日本電気株式会社 浮動小数点データ総和演算回路
NL9000917A (nl) * 1989-10-25 1991-05-16 Holland Biotechnology Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van (precursor) eiwitten en voor de (micro) biologische bereiding van eiwitten.
CN1024746C (zh) * 1989-12-20 1994-06-01 李清祈 具热能调节作用构件的煮器
EP0574402B2 (en) * 1990-11-26 2012-08-01 Genetics Institute, LLC Expression of pace in host cells and methods of use thereof
US5780285A (en) * 1995-03-03 1998-07-14 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing dibasic residues
MXPA03008229A (es) 2001-03-14 2004-11-12 Lilly Co Eli Trienos fluorados y su uso como moduladores rxr.

Also Published As

Publication number Publication date
IE914102A1 (en) 1992-06-03
EP0785273A1 (en) 1997-07-23
CA2096418C (en) 2001-11-20
DE69127829D1 (de) 1997-11-06
EP0574402A1 (en) 1993-12-22
JPH06504435A (ja) 1994-05-26
WO1992009698A1 (en) 1992-06-11
JP4236698B2 (ja) 2009-03-11
ES2109336T3 (es) 1998-01-16
CA2096418A1 (en) 1992-05-27
ATE158816T1 (de) 1997-10-15
EP0574402A4 (en) 1994-08-24
US5986079A (en) 1999-11-16
EP0574402B1 (en) 1997-10-01
DK0574402T3 (da) 1998-05-18
EP0574402B2 (en) 2012-08-01
DE69127829T2 (de) 1998-03-19
US5965425A (en) 1999-10-12
US5460950A (en) 1995-10-24

Similar Documents

Publication Publication Date Title
JP2008194050A (ja) 宿主細胞でのpaceの発現およびその使用法
ATE77104T1 (de) Menge und verfahren zur herstellung rekombinierter erzeugnisse in grosser ausbeute.
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
JP2014012738A (ja) 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
DK200401261A (da) Ekspression af faktor VII og IX aktiviteter i pattedyrceller
CA2168429A1 (en) Expression of fusion polypeptides transported out of cytoplasm without leader sequences
HUT43630A (en) Mammalian interleukine-4 and process for producing it
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
CA2001303A1 (en) Endothelin dna and use thereof
DE69032598D1 (de) Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
AU2885295A (en) Novel hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
DK163937B (da) Strukturelt gen, som koder for autentisk humant serumalbumin til ekspression i en ikke-human vaert, fremgangsmaade til fremstilling deraf, rekombinant-dna-molekyle indeholdende genet, vaertsorganisme transformeret dermed og fremgangsmaade til fremstilling af autentisk humant serumalbumin
EP0322226B1 (en) Site-directed mutagenesis modified glycoprotein hormones and methods of use
KR930013115A (ko) Dna 분자 및 숙주
JP2003529608A5 (ja)
CA2298412A1 (en) Identification of human cell lines for the production of human proteins by endogenous gene activation
JPS63251084A (ja) 新規化合物、その製法及びそれを含む医薬組成物
JP2003514532A5 (ja)
ATE109506T1 (de) Hefestämme für die herstellung von heterologen reifen proteinen, besonders von hirudin.
EP0284898A3 (de) Hinge-Peptid, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung synthetischer Immunogene
AUPM772494A0 (en) Improvements in production of proteins in host cells
DE3469440D1 (en) Improved steroid esters preparation
GR80059B (en) Method for preparing sekretin
CZ287035B6 (en) Process for preparing soluble recombinant proteins from bacterial cells
JPS646298A (en) Novel physiologically active polypeptide

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081209

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090511